首頁 > 市場調查報告書 > 製藥

神經疾病疼痛

市場調查報告書

商品編碼

1608876

神經痛治療藥物市場：依藥物類型、給藥途徑、嚴重程度、通路及地區分類

Neuralgia Treatment Market, By Drug Type (Anticonvulsants, Antidepressants, Opioids, Non-steroidal anti-inflammatory Drugs, and Others), By Route of Administration, By Severity, By Distribution Channel, By Geography

出版日期: 2024年11月20日 | 出版商:

Coherent Market Insights | 英文 172 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球神經痛治療市場規模為24.1億美元，2031年將達37.2億美元，2024年至2031年複合年成長率為6.4%。

分析範圍		分析詳情
基準年	2023年	市場規模（2024年）	24.1億美元
實際資料	2019-2023	預測期	2024-2031
預測期複合年成長率（2024-2031）	6.40%	預計金額（2031年）	37.2億美元

圖：2024年神經痛治療藥物市場佔有率（%），依地區

神經痛，也稱為神經病變疼痛，是由影響體感神經系統的損傷或疾病引起的慢性疼痛。它的特徵是射擊、刺傷或劇烈的疼痛，這種疼痛可能會被誇大或不可預測。常見的神經痛類型包括三叉神經痛、帶狀帶狀皰疹後遺症神經痛和纖維肌痛。近年來，由於神經病變疼痛疾病的盛行率不斷上升以及易患此類疾病的老年人口數量不斷增加，全球神經疼痛治療市場出現了成長。此外，療效提高且副作用最小的新藥的開發也推動了對神經疼痛治療的需求。

市場動態：

全球神經性疼痛藥物市場是由神經病變疼痛疾病發病率不斷上升以及世界老年人口不斷成長所推動的。由於神經系統與老齡化相關的退化性變化，神經病變疼痛疾病在老年人中更為常見。此外，比傳統治療方法具有更高功效和更好安全性的新藥的市場開拓正在推動市場成長。Carbamazepine和Gabapentin是常用於治療神經疼痛的專利到期藥物。然而，這些藥物存在耐受性和依從性差的問題。因此，正在研究和開發具有改善的風險和益處的新治療劑，例如鈉通道阻斷劑、NMDA受體拮抗劑和α2δ配體。另一方面，緩解疾病療法的短缺和新療法的高價格構成了挑戰，在一定程度上限制了市場的擴張。然而，隨著疼痛管理意識的提高和學名藥的出現，未來幾年將為神經疼痛治療市場的參與者創造巨大的商機。

本研究的主要特點

該報告對全球神經痛治療藥物市場進行了詳細分析，包括以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。做。

它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。

根據公司亮點、產品系列、主要亮點、績效和策略等參數，提供全球神經痛治療市場主要企業的概況。

研究涵蓋的主要企業包括葛蘭素史克(GlaxoSmithKline Plc PLC)、輝瑞公司(Pfizer Inc.)、諾華(Novartis AG)、百健(Biogen)、卡迪拉醫療保健有限公司(Cadila Healthcare Limited)、靈北製藥(Lundbeck Pharmaceuticals LLC) 和梯瓦製藥工業有限公司(Teva Pharmaceutical Industries Limited)、賽諾菲SA (Sanofi SA)、安進公司(Amgen Inc.)、禮來公司(Eli Lilly & Company)、安斯泰來製藥(Astellas Pharma) 和強生公司 (Johnson)。還有A/S等。

該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

全球神經疼痛治療藥物市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

透過用於分析全球神經疼痛治療藥物市場的各種策略矩陣，將有助於相關人員做出決策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	2.41 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	6.40%	2031 Value Projection:	3.72 Bn

Neuralgia, also known as neuropathic pain, is a chronic pain caused by damage or disease affecting the somatosensory nervous system. It is characterized by shooting, stabbing, and sharp pain that feels exaggerated or unpredictable. Some common types of neuralgia include trigeminal neuralgia, postherpetic neuralgia caused by shingles, and fibromyalgia. The global neuralgia treatment market has been witnessing growth in recent times owing to the rising prevalence of neuropathic pain disorders and growing geriatric population who are more prone to such conditions. Furthermore, the development of novel drugs providing improved efficacy and minimal side effects are also fueling the demand for neuralgia treatments.

Market Dynamics:

The global neuralgia treatment market is driven by the increasing incidence of neuropathic pain disorders coupled with the growing geriatric population globally. Neuropathic pain conditions are more prevalent in the elderly due to age-related degenerative changes in the nervous system. Additionally, the market growth is facilitated by the development of newer drugs offering enhanced efficacy and favorable safety profiles over conventional treatment options. Carbamazepine and gabapentin are off-patent drugs commonly used to treat neuralgia. However, their tolerability issues lead to poor compliance. This has triggered R&D of novel therapeutic classes like sodium channel blockers, NMDA receptor antagonists, and alpha-2 delta ligands that demonstrate improved risk-benefit ratios. On the other hand, lack of disease-modifying treatments and high cost of newer therapies are some challenges restraining the market expansion to a certain extent. Nevertheless, rise in awareness about pain management and availability of generic versions of branded drugs create huge opportunities for the neuralgia treatment market players in the coming years.

Key Features of the Study:

This report provides in-depth analysis of the global neuralgia treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global neuralgia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include GlaxoSmithKline PLC, Pfizer Inc., Novartis AG, Biogen, Cadila Healthcare Limited, Lundbeck Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Amgen Inc., Eli Lilly and Company, Astellas Pharma Inc., Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., and H. Lundbeck A/S.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global neuralgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuralgia treatment market

Market Segmentation

Drug Type Insights (Revenue, USD Bn, 2019 - 2031)
- Anticonvulsants
- Antidepressants
- Opioids
- Non-steroidal anti-inflammatory Drugs (NSAIDs)
- Others
Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Intravenous
- Transdermal
- Others
Severity Insights (Revenue, USD Bn, 2019 - 2031)
- Mild
- Moderate
- Severe
Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- GlaxoSmithKline PLC
- Pfizer Inc.
- Novartis AG
- Biogen
- Cadila Healthcare Limited
- Lundbeck Pharmaceuticals LLC
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Amgen Inc.
- Eli Lilly and Company
- Astellas Pharma Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- AbbVie Inc.
- Lundbeck A/S

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Neuralgia Treatment Market, By Drug Type
- Global Neuralgia Treatment Market, By Route of Administration
- Global Neuralgia Treatment Market, By Severity
- Global Neuralgia Treatment Market, By Distribution Channel
- Global Neuralgia Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Neuralgia Treatment Market, By Drug Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Non-steroidal anti-inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Neuralgia Treatment Market, By Route of Administration, 2019-2031 (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Neuralgia Treatment Market, By Severity, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Mild
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Moderate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Severe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Neuralgia Treatment Market, By Distribution Channel, 2019-2031 (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Neuralgia Treatment Market, By Region, 2019 - 2031, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cadila Healthcare Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Amgen Inc.
Eli Lilly and Company
Astellas Pharma Inc.
Johnson & Johnson
Merck & Co., Inc.
AbbVie Inc.
Lundbeck A/S